Investing in Biotech from Horizon 3 Biotech

Hosted by Horizon 3 Biotech Chief Investment Officer Matt McNamara. In this episode, Matt is joined by Jackie Fairley -  CEO at Starpharmas & Scott Power - Investment Analyst at Morgans & Horizon 3 Biotech Investment Community Member.

Hosted by Horizon 3 Biotech Chief Investment Officer Matt McNamara. In this episode, Matt is joined by John McCutcheon - President & CEO at President and CEO at EBR Systems & Elyse Shapiro - Healthcare Analyst at from Canaccord Genuity.

Hosted by Horizon 3 Biotech Chief Investment Officer Matt McNamara. In this episode, Matt is joined by Dr Megan Baldwi - CEO and Managing Director at Opthea Limited & Daniel Sharp from Canaccord Genuity, one of the most experienced biotech fundraisers in the Australian Market.

Hosted by Horizon 3 Biotech Chief Investment Officer Matt McNamara. In this episode Matt is joined by Amir Zalcenstein - Managing Director at CNJ Ventures & Leslie Chong - Chief Executive Officer and Managing Director at Imugene Limited.

Mike and Ben talk about Scott Galloway's theory of the Great Dispersion - the impact of COVID on business models like direct-to-consumer and how far they're spreading

Hosted by Horizon 3 Biotech Chief Investment Officer Matt McNamara. In this episode Matt is joined by Michael Woods of Newburyport Partners, Dr John Melki Director & CEO at Genetic Signatures & Dr Paul Gavin - CEO of Avecho Biotechnologies.

Hosted by Horizon 3 Biotech Chief Investment Officer Matt McNamara In this episode Matt will be joined by Scott Power of Morgans and Jon Pilcher, CEO of Neuren Pharmaceuticals.

This podcast accompanies Horizon 3 Biotech's BioBullets email for the 13th August 2021

Hosted by Horizon 3 Biotech Chief Investment Officer Matt McNamara In this episode Matt will be joined by Dr Deborah Rathjen, CEO of Carina Biotech and Simon Davidson, Partner at Lander & Rogers

Hosted by Horizon 3 Biotech Chief Investment Officer Matt McNamara In this episode Matt will be joined by Dirk van Dissel of Candour Advisory and Chris Baldwin, Deputy CEO and Chief Commercial Officer of Exopharm.